FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to pharmacology, and concerns using the known bis-monosuccinyl-methionyl-serine heptamethylenediamide as an agent for treating and preventing opioid addiction. Bis-monosuccinyl-methionyl-serine heptamethylenediamide (GSB-214) in doses of 0.1–5.0 mg/kg with a single intraperitoneal administration dose-dependently prevents morphine withdrawal-induced abrupt drop in body weight and reduces severity of behavioral signs of morphine withdrawal syndrome in outbred male rats, in particular, reducing the total WS index of morphine withdrawal by 41.5% and reducing diarrhea by 96.7% in the most effective dose of 1.0 mg/kg, as well as eliminating ptosis in all studied doses.
EFFECT: compound GSB-214 in dose of 1 mg/kg with subchronic intraperitoneal introduction for 6 days prevents formation of tolerance to analgesic action of morphine with thermal stimulation.
1 cl, 3 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LOW-MOLECULAR MIMETIC BDNF AS AN AGENT FOR TREATING OPIOID DEPENDENCE | 2019 |
|
RU2707301C1 |
| MEANS FOR OPIOID ABSTINENCE SYNDROME ARRESTING | 2017 |
|
RU2643588C1 |
| LOW MOLECULAR WEIGHT MIMETIC OF BRAIN NEUROTROPHIC FACTOR WITH ANALGESIC, ANXIOLYTIC AND ANTIADDICTIVE EFFECTS | 2020 |
|
RU2759023C2 |
| AGENT POSSESSING ANTIDIABETIC ACTIVITY | 2017 |
|
RU2693479C2 |
| ANALGESIC AGENT FOR VISCERAL PAIN MANAGEMENT | 2010 |
|
RU2429874C1 |
| MEDICATION FOR WITHDRAWAL SYNDROME MANAGEMENT IN OPIATE DEPENDENCE | 2012 |
|
RU2485954C1 |
| ANALGESIC AGENT AND THERAPY OF PAIN SYNDROME OF VARIOUS AETIOLOGIES BY USING SAID AGENT | 2007 |
|
RU2367432C2 |
| USE OF SIGMA LIGANDS WITH INDUCED OPIOIDS HYPERALGESIA | 2011 |
|
RU2589899C2 |
| METHOD FOR PREVENTION ABUSE WITH OPIOID- -CONTAINING MEDICINAL FORMULATIONS | 1998 |
|
RU2228180C2 |
| APPLICATION OF ANTAGONISTS OF OPIOID RECEPTORS IN CASE OF GASTROINTESTINAL TRACT DISEASES | 2010 |
|
RU2561873C2 |
